Cullinan Therapeutics Ownership | Who Owns Cullinan Therapeutics?

Cullinan Therapeutics Ownership Summary

Cullinan Therapeutics is owned by 121.70% institutional investors, 0.43% insiders. Bioimpact capital is the largest institutional shareholder, holding 16.44% of CGEM shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 3.64% of its assets in Cullinan Therapeutics shares.

CGEM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Cullinan Therapeutics	121.70%	0.43%	-22.13%
Sector	Healthcare Stocks	245.07%	12.10%	-157.17%
Industry	Biotech Stocks	380.48%	11.73%	-292.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bioimpact capital	9.73M	16.44%	$177.21M
Lynx1 capital management lp	8.96M	15.14%	$163.23M
Bvf inc/il	5.75M	9.71%	$104.72M
Blackrock funding, inc. /de	5.23M	8.84%	$95.29M
Blackrock	3.55M	8.25%	$61.92M
Price t rowe associates inc /md/	3.83M	6.46%	$69.67M
State street	3.67M	6.20%	$66.81M
Vanguard group	3.30M	5.59%	$34.14M
Kynam capital management, lp	3.11M	5.26%	$56.71M
Vanguard capital management	2.61M	4.42%	$47.60M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lynx1 capital management lp	8.96M	32.16%	$163.23M
Bioimpact capital	9.73M	10.81%	$177.21M
Blue owl capital lp	1.54M	4.22%	$28.04M
Kynam capital management, lp	3.11M	3.13%	$56.71M
Boone capital management	704.44K	3.00%	$12.83M
Bvf inc/il	5.75M	2.68%	$104.72M
Nextech invest	1.14M	2.25%	$13.90M
Twin focus capital partners	595.49K	1.10%	$10.84M
Great point partners	300.00K	1.03%	$5.46M
Bleichroeder lp	250.00K	0.81%	$4.55M

Top Buyers

Holder	Shares	% Assets	Change
Bioimpact capital	9.73M	10.81%	2.08M
Price t rowe associates inc /md/	3.83M	0.01%	1.80M
State street	3.67M	0.00%	1.12M
Blackrock	3.55M	0.00%	1.12M
Artal group	1.06M	0.47%	1.06M

Top Sellers

Holder	Shares	% Assets	Change
Paradigm biocapital advisors lp	-	-	-2.32M
Holocene advisors, lp	-	-	-1.53M
Nextech invest	-	-	-1.14M
Cormorant asset management, lp	-	-	-1.13M
Marshall wace, llp	66.05K	0.00%	-983.53K

New Positions

Holder	Shares	% Assets	Change	Value
Artal group	1.06M	0.47%	1.06M	$18.45M
Boone capital management	704.44K	3.00%	704.44K	$12.83M
Boxer capital	657.89K	0.60%	657.89K	$11.47M
Sixth street partners management company	464.03K	0.00%	464.03K	$8.45M
Perceptive advisors	426.48K	0.12%	426.48K	$7.77M

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-5.00
Capital performance advisors llp	-13.00
Versant capital management	-23.00
Corecap advisors	-29.00
Amundi	-40.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	191	7.91%	72,049,049	9.90%	121	0.99%	118	18.00%	45	7.14%
Mar 31, 2026	76	-51.28%	21,564,544	-65.87%	36	0.32%	48	-48.39%	15	-64.29%
Dec 31, 2025	87	-40.00%	24,287,663	-60.24%	41	0.38%	54	-36.47%	24	-33.33%
Sep 30, 2025	141	2.92%	61,105,493	3.70%	103	1.04%	81	20.90%	35	-14.63%
Jun 30, 2025	144	-4.00%	62,598,313	-3.20%	106	0.88%	69	1.47%	44	-16.98%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
State Street® SPDR® S&P® Biotech ETF	2.34M	3.64%	5.38K
Vanguard Morn Total Stk Mkt Idx Investor	1.93M	3.14%	73.80K
Vanguard Total Stock Mkt Idx Inv	1.93M	3.14%	73.80K
Vanguard MStar Total Stk Mkt Idx Invest	1.95M	3.04%	24.93K
Vanguard US Total Market Shares ETF	1.50M	2.57%	-
iShares Russell 2000 ETF	1.54M	2.40%	-27.46K
T. Rowe Price New Horizons	1.02M	1.66%	201.10K
US Small-Cap Growth II Equity Comp	1.02M	1.66%	595.33K
Franklin US Small Cap Growth Equity	849.95K	1.44%	64.90K
Franklin Small Cap Growth SMA	849.95K	1.44%	849.91K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 08, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$172.56K
Aug 13, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$607.80K
Jul 06, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$142.56K
May 05, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$113.88K
May 05, 2026	Michaelson Jennifer	Chief Scientific Officer	Sell	$3.12K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	3
2026 Q2	-	2
2026 Q1	-	15
2025 Q4	8	8
2025 Q3	-	-

CGEM Ownership FAQ

Who Owns Cullinan Therapeutics?

Cullinan Therapeutics shareholders are primarily institutional investors at 121.70%, followed by 0.43% insiders and -22.13% retail investors. The average institutional ownership in Cullinan Therapeutics's industry, Biotech Stocks , is 380.48%, which Cullinan Therapeutics falls below.

Who owns the most shares of Cullinan Therapeutics?

Cullinan Therapeutics’s largest shareholders are Bioimpact capital (9.73M shares, 16.44%), Lynx1 capital management lp (8.96M shares, 15.14%), and Bvf inc/il (5.75M shares, 9.71%). Together, they hold 41.29% of Cullinan Therapeutics’s total shares outstanding.

Does Blackrock own Cullinan Therapeutics?

Yes, BlackRock owns 8.25% of Cullinan Therapeutics, totaling 3.55M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.92M$. In the last quarter, BlackRock increased its holdings by 1.12M shares, a 46.16% change.

Who is Cullinan Therapeutics’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is Cullinan Therapeutics’s biggest shareholder by percentage of total assets invested, with 32.16% of its assets in 8.96M Cullinan Therapeutics shares, valued at 163.23M$.

Who is the top mutual fund holder of Cullinan Therapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Cullinan Therapeutics shares, with 3.64% of its total shares outstanding invested in 2.34M Cullinan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools